|
시장보고서
상품코드
2078305
세균 백신 시장 : 백신 유형별, 환자 연령층별, 투여 경로별, 유통 채널별, 지역별Bacterial Vaccines Market, By Vaccine Type, By Patient Age Group, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
세균 백신 시장은 2026년에 299억 9,000만 달러, 2033년까지 520억 7,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 8.2%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 299억 9,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.20% | 2033년 시장 규모 예측 : | 520억 7,000만 달러 |
세균 백신에는 면역 체계를 활성화시키는 약독화되거나 불활성화된 세균이 포함되어 있습니다. 이는 결핵, 콜레라, 탄저, 인플루엔자, 파상풍, 수막염, 장티푸스 등의 감염병과 싸우기 위한 예방 의학에서 매우 중요한 방법입니다. 정부와 비정부기구(NGO)는 감염병 백신을 포함한 예방의학의 이점에 대한 인식을 확산하기 위해 여러 프로그램을 시행하고 있습니다.
시장 역학:
세계 세균 백신 시장은 예측 기간 동안 상당한 성장률을 보일 것으로 예측됩니다. 이는 주로 치명적인 감염병에 대한 예방 의료를 전 세계 사람들이 이용할 수 있도록 하기 위해 세계 각국 정부가 시행하고 있는 중요한 조치 덕분입니다. 또한, 팬데믹 기간 중 백신 접종 수요 증가도 시장 성장을 뒷받침하고 있습니다. 또한, 감염병에 대한 새로운 데옥시리보핵산(DNA) 백신의 출시도 시장 성장을 견인하고 있습니다. 항생제 내성균에 의한 질병 발생률 증가 역시 세균 백신 시장의 성장을 가속하고 있습니다. 이에 따라 주요 시장 참여자들은 감염병에 대한 보다 효과적인 백신 개발에 주력하며, 연구 활동에 대한 투자를 확대되고 있습니다.
그러나 세균성 질환에 대한 인식 부족이 세균 백신 시장의 성장을 저해할 것으로 예측됩니다.
예를 들어, 2023년 9월 28일, 영국 정부는 항생제 내성(AMR)에 맞선 전 세계적 노력의 일환으로 감염병 발생을 예방하고, 세균 백신 개발을 가속화하기 위해 버밍엄 대학교가 주도하는 ‘ 세균 백신 네트워크(BactiVac)”에 대해 140만 달러의 자금 지원을 실시했습니다. 세균 백신은 감염증의 발병을 예방하는 동시에 항생제 사용 필요성을 줄임으로써, 항생제 내성(AMR)과의 싸움에서 매우 중요한 역할을 하고 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 세균 백신 시장의 주요 기업 프로파일을 소개했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 유형 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 세계 세균 백신 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 세계 세균 백신 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 세균 백신 시장 : 백신 유형별, 2021년-2033년
제5장 세계의 세균 백신 시장 : 환자 연령층별, 2021년-2033년
제6장 세계의 세균 백신 시장 : 투여 경로별, 2021년-2033년
제7장 세계의 세균 백신 시장 : 유통 채널별, 2021년-2033년
제8장 세계의 세균 백신 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.07.10Bacterial Vaccines Market is estimated to be valued at USD 29.99 Bn in 2026 and is expected to reach USD 52.07 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 29.99 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 52.07 Bn |
Bacterial vaccines contain mild or killed forms of bacteria that activate the immune system. This is a vital method for preventive medicine to fight infections like tuberculosis, cholera, anthrax, influenza, tetanus, meningitis, and typhoid. Several programs are carried out by governments and non-governmental organizations to spread awareness about the benefits of the preventive medicines including vaccines against infectious diseases.
Market Dynamics:
Global bacterial vaccines market is expected to grow at a substantial rate during the forecast period. This is mainly due to significant initiatives undertaken by governments across the globe to ensure that the preventive medicine for lethal infectious diseases is available for the population across the world. The market is also fueled by the increasing demand for vaccinations during pandemics. Moreover, the market is driven by the launch of new Deoxyribonucleic acid (DNA) vaccines against infectious diseases. The rising incidence of antibiotic-resistant bacterial diseases is again driving the growth of bacterial vaccines market. This is influencing the key market players to invest in research activities by focusing on developing more effective vaccines against infectious diseases.
However, lack of awareness regarding the bacterial disease is expected to hinder the market growth of the bacterial vaccines
For instance, on September 28, 2023, the U.K. government awarded the University of Birmingham-hosted Bacterial Vaccines Network (BactiVac) US$ 1.4 million in funding to accelerate the development of bacterial vaccines in a bid to prevent infections from occurring as part of the global fight against antimicrobial resistance (AMR). Bacterial vaccines play a critical role in the fight against AMR, both through preventing infections from developing and reducing the need to use antimicrobials.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global bacterial vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc., Pfizer Inc., Merck & Co., Inc., Sanofi, Johnson & Johnson Service, Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech Biological E. Limited, Astellas Pharma Inc., Seqirus (CSL Limited), AstraZeneca, Novavax, Inc., Bavarian Nordic A/S, Emergent BioSolutions Inc., Valneva SE, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Immunomic Therapeutics, Inc., Moderna, Inc., Clover Biopharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global bacterial vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bacterial vaccines market
Global Bacterial Vaccines Detailed Segmentation:
- By Vaccine Type (Revenue, USD Bn, 2021 - 2033)
- Pertussis (Whooping Cough) Vaccines
- Tetanus Vaccines
- Diphtheria Vaccines
- Pneumococcal Vaccines
- Meningococcal Vaccines
- Typhoid Vaccines
- Tuberculosis (TB) Vaccines
- Cholera Vaccines
- Shigellosis Vaccines
- Others
- By Patient Age Group (Revenue, USD Bn, 2021 - 2033)
- Pediatric Vaccines (Infants, Children)
- Adolescent Vaccines
- Adult Vaccines
- Geriatric Vaccines
- By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Intramuscular
- Intravenous
- Subcutaneous
- Others (Oral, Nasal among others)
- By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Public
- Private
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profile
- GSK Plc
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Service, Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Biological E. Limited
- Astellas Pharma Inc.
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax, Inc.
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Valneva SE
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Immunomic Therapeutics, Inc.
- Moderna, Inc.
- Clover Biopharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Vaccine Type
- Market Snippet, By Patient Age Group
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraints
- Opportunities
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Bacterial Vaccines Market, By Vaccine Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pertussis (Whooping Cough) Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Tetanus Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Diphtheria Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Pneumococcal Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Meningococcal Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Typhoid Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Tuberculosis (TB) Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Cholera Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Shigellosis Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Bacterial Vaccines Market, By Patient Age Group, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric Vaccines (Infants, Children)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Adolescent Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Adult Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Geriatric Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Global Bacterial Vaccines Market, By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Global Bacterial Vaccines Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Global Bacterial Vaccines Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Vaccine Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age Group, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Company Profie
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Johnson & Johnson Service, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biological E. Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Seqirus (CSL Limited)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novavax, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bavarian Nordic A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Emergent BioSolutions Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Valneva SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Immunomic Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Clover Biopharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analysts' Views
- GSK plc
10. Section
- References
- Research Methodology
- About us
